Literature DB >> 31285290

The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis.

Rachele Invernizzi1, Philip L Molyneaux2,3.   

Abstract

Idiopathic pulmonary fibrosis (IPF) arises in genetically susceptible individuals as a result of an aberrant wound-healing response following repetitive alveolar injury. The clinical course of the disease remains both variable and unpredictable with periods of more rapid decline, termed acute exacerbation of IPF (AE-IPF), often punctuating the disease trajectory. Exacerbations carry a significant morbidity and mortality, and their exact pathogenesis remains unclear. Given the emerging evidence that disruption and alteration in the lung microbiome plays a role in the pathogenesis and progression of IPF, this review discusses the current knowledge of the contribution of infection and the respiratory microbiome to AE-IPF.
Copyright ©ERS 2019.

Entities:  

Year:  2019        PMID: 31285290     DOI: 10.1183/16000617.0045-2019

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  9 in total

1.  Essential role of IL-17 in acute exacerbation of pulmonary fibrosis induced by non-typeable Haemophilus influenzae.

Authors:  Shengsen Chen; Xinyun Zhang; Cheng Yang; Shi Wang; Hao Shen
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

Review 2.  Airway Microbiota as a Modulator of Lung Cancer.

Authors:  Taichiro Goto
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 3.  Microbiome dysbiosis in lung cancer: from composition to therapy.

Authors:  Ning-Ning Liu; Qiang Ma; Yang Ge; Cheng-Xiang Yi; Lu-Qi Wei; Jing-Cong Tan; Qiao Chu; Jing-Quan Li; Peng Zhang; Hui Wang
Journal:  NPJ Precis Oncol       Date:  2020-12-10

Review 4.  An integrated perspective on transmutation of acute inflammation into chronic and the role of the microbiome.

Authors:  George Vithoulkas
Journal:  J Med Life       Date:  2021 Nov-Dec

5.  Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis.

Authors:  Athina Trachalaki; Eliza Tsitoura; Semeli Mastrodimou; Rachele Invernizzi; Eirini Vasarmidi; Eleni Bibaki; Nikolaos Tzanakis; Philip L Molyneaux; Toby M Maher; Katerina Antoniou
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

Review 6.  The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis.

Authors:  Paolo Spagnolo; Philip L Molyneaux; Nicol Bernardinello; Elisabetta Cocconcelli; Davide Biondini; Federico Fracasso; Mariaenrica Tiné; Marina Saetta; Toby M Maher; Elisabetta Balestro
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923

7.  Acute Exacerbation of Interstitial Lung Disease in Adult Patients With Idiopathic Inflammatory Myopathies: A Retrospective Case-Control Study.

Authors:  Junyu Liang; Heng Cao; Yini Ke; Chuanyin Sun; Weiqian Chen; Jin Lin
Journal:  Front Med (Lausanne)       Date:  2020-01-31

8.  The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis.

Authors:  Rachele Invernizzi; Benjamin G Wu; Joseph Barnett; Poonam Ghai; Shaun Kingston; Richard J Hewitt; Johanna Feary; Yonghua Li; Felix Chua; Zhe Wu; Athol U Wells; Peter M George; Elisabetta A Renzoni; Andrew G Nicholson; Alexandra Rice; Anand Devaraj; Leopoldo N Segal; Adam J Byrne; Toby M Maher; Clare M Lloyd; Philip L Molyneaux
Journal:  Am J Respir Crit Care Med       Date:  2021-02-01       Impact factor: 21.405

9.  Treatment Outcomes of Infectious and Non-infectious Acute Exacerbation of Myositis-Related Interstitial Lung Disease.

Authors:  Hyun Lee; Sung Jun Chung; Sang Hyuk Kim; Hayoung Choi; Youlim Kim; Tai Sun Park; Dong Won Park; Ji-Yong Moon; Sang-Heon Kim; Tae Hyung Kim; Ho Joo Yoon; Jang Won Sohn
Journal:  Front Med (Lausanne)       Date:  2022-03-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.